Delivery Order SPE2DB20D3103-SPE2DB23FN0A5
- Not listed
- This federal contract award is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on December 5, 2024, with a ceiling value of $12,729.15 and a completion date of December 6, 2024. This is a delivery order contract with a firm fixed price pricing type. The contract is not designated with a set-aside requirement,...
- This federal contract award is for the delivery of Rebif 44 mcg/0.5 mL syringes to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $127,917.04 and an ultimate completion date of July 28, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is also registered in the System...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,540.37, is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty pharmaceutical product. This is a delivery order contract, with a firm fixed-price pricing type, and an ultimate completion date of December 18, 2024. The contract does not have a set-aside designation, indicating open...
- This federal contract award is for the delivery of REBIF REBIDOSE 44 MCG/0.5 ML 0.5ML, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $8,206.68 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of July 30, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the...
- This federal contract award, valued at $12,303.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the provision of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty medication. The contract has an ultimate completion date of October 21, 2024 and does not have a set-aside designation, indicating open competition. Amerisourcebergen, the prime contractor, is a...
- This federal contract award is for the delivery of the pharmaceutical product REBIF 44 MCG/0.5 ML SYRINGE 0.5ML to the Defense Logistics Agency (DLA), a defense agency. The $18,675.71 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The contract has an ultimate completion date of June 4, 2024 and does not have a set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC)...
- This federal contract award is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML pharmaceuticals to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $9,980.49, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a delivery order with a firm fixed price and has an ultimate completion date of October 25, 2023. This award is not a set-aside contract. Amerisourcebergen Drug Corp...
- This federal contract award is for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $49,001.93, is a delivery order awarded to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract has a firm fixed-price pricing type and an ultimate completion date of August 29, 2024. This contract is not associated...
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of Amerisourcebergen Corporation, for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML pharmaceutical product. The $33,745.79 firm fixed price contract has an ultimate completion date of April 18, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, valued up to $999,999,999.00...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,437.19, is a Firm Fixed Price Delivery Order for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML. The contract has an ultimate completion date of February 12, 2025 and was awarded on February 11, 2025. This contract award is part of a larger Indefinite Delivery Contract (IDC) valued at...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB23FN0A5Delivery Order
This federal contract award is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, which has a value of $16,757.61, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on April 6, 2023. The contract has an ultimate completion date of April 7, 2023 and is a Firm Fixed Price Delivery Order. Amerisourcebergen Drug Corp is a for-profit organization that is registered in the System for Award Management (SAM.gov) and has extensive experience providing pharmaceutical and medical supplies to federal government agencies, particularly within military and veterans' healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award does not have a set-aside designation, indicating open competition. The DLA, which is a defense agency, is the funding agency for this contract.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.8k | 4/6/23 |